Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis
Authors:
Open Access
- 17 November 2023
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 31 (2)
Abstract
Background and purpose: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects adults, characterized by muscle weakness resulting from the specific death of motor neurons in the spinal cord and brain. The pathogenesis of ALS is associated with the accumulation of mutant superoxide dismutase 1 (SOD1) proteins and neurofilaments in motor neurons, highlighting the critical need for disease‐modifying treatments. Current therapies, such as riluzole and edaravone, provide only symptomatic relief. Recently, tofersen gained approval from the US FDA under the brand name Qalsody as the first and only gene therapy for ALS, addressing a significant pathological aspect of the disease.Methods: We carried out a literature survey using PubMed, Scopus, National Institutes of Health, and Biogen for articles published in the English language concerned with “amyotrophic lateral sclerosis”, pathophysiology, current treatment, treatment under clinical trial, and the newly approved drug “tofersen” and its detailed summary.Results: A comprehensive review of the literature on the pathophysiology, available treatment, and newly approved drug for this condition revealed convincing evidence that we are now able to better monitor and treat ALS.Conclusions: Although treatment of ALS is difficult, the newly approved drug tofersen has emerged as a potential therapy to slow down the progression of ALS by targeting SOD1 mRNA, representing a significant advancement in the treatment of ALS.Keywords
This publication has 40 references indexed in Scilit:
- The Complex Molecular Biology of Amyotrophic Lateral Sclerosis (ALS)2012
- Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementiaNature, 2011
- Safety, Tolerability, and Cerebrospinal Fluid Penetration of Ursodeoxycholic Acid in Patients With Amyotrophic Lateral SclerosisClinical Neuropharmacology, 2010
- The Structure of Human Extracellular Copper–Zinc Superoxide Dismutase at 1.7 Å Resolution: Insights into Heparin and Collagen BindingJournal of Molecular Biology, 2009
- ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1Genes & Development, 2008
- Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS miceProceedings of the National Academy of Sciences, 2008
- Antisense oligonucleotide therapy for neurodegenerative diseaseJournal of Clinical Investigation, 2006
- Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosisJournal of Neurochemistry, 2004
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993